ArticleJournal of geriatric cardiology : JGC2012
Atherosclerosis: from biology to pharmacological treatment.
Article in Journal of geriatric cardiology : JGC, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Role of Extracellular Vesicles in Chronic Post-Embolic Pulmonary Hypertension: Data from an Experimental Animal Model and Patients.Biomedicines · 2025Article
- Supplementation with the Postbiotic BPL1™-HT (Heat-InactivatedAntioxidants (Basel, Switzerland) · 2025Article
- Fluid-structure interaction (FSI) simulation for studying the impact of atherosclerosis on hemodynamics, arterial tissue remodeling, and initiation risk of intracranial aneurysms.Biomechanics and modeling in mechanobiology · 2022Article
- Impact of Non-Pharmacological Interventions on the Mechanisms of Atherosclerosis.International journal of molecular sciences · 2022Review
- CHOP Increases TRIB3-Dependent miR-208 Expression to Potentiate Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating TIMP3 in Atherosclerosis.Cardiovascular drugs and therapy · 2022Article
- The Effect and Safety of Xuefu Zhuoyue Prescription for Coronary Heart Disease: An Overview of Systematic Reviews and Meta-Analyses.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Therapeutic Response of miR-145 Micelles on Patient-Derived Vascular Smooth Muscle Cells.Frontiers in digital health · 2022Article
- LncRNA BANCR induced vascular smooth muscle cell proliferation by downregulating miR-34c methylation in atherosclerosis.Journal of thrombosis and thrombolysis · 2021Article
- The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1.Journal of personalized medicine · 2021Review
- Network Pharmacology Study on Molecular Mechanisms of Zhishi Xiebai Guizhi Decoction in the Treatment of Coronary Heart Disease.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Time-Dependent Risk of Acute Myocardial Infarction in Patients With Alopecia Areata in Korea.JAMA dermatology · 2020Article
- Expression of Hypoxia-Inducible Factor-1α (HIF1A) and Lp-PLA2 in Low, Intermediate, and High Cardiovascular Disease Risk Population.Vascular health and risk management · 2020Article
- High-Fat Diets and LXRs Expression in Rat Liver and Hypothalamus.Cellular and molecular neurobiology · 2019Article
- Glycocalyx in Atherosclerosis-Relevant Endothelium Function and as a Therapeutic Target.Current atherosclerosis reports · 2017Review
- Roles and Mechanisms of Obstructive Sleep Apnea-Hypopnea Syndrome and Chronic Intermittent Hypoxia in Atherosclerosis: Evidence and Prospective.Oxidative medicine and cellular longevity · 2016Review
- Intra-Arterial Drug and Light Delivery for Photodynamic Therapy Using Visudyne®: Implication for Atherosclerotic Plaque Treatment.Frontiers in physiology · 2016Article
- Effects of Selenium in the MAPK Signaling Cascade.Journal of cardiovascular and thoracic research · 2015Article
- Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.Scientific reports · 2014Article
- Polymorphisms of genes involved in polycyclic aromatic hydrocarbons' biotransformation and atherosclerosis.Biochemia medica · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent explosion in the amount of cardiovascular risk has swept across the globe. Primary prevention is the preferred method to lower cardiovascular risk. Lowering the prevalence of obesity is the most urgent matter, and is pleiotropic since it affects blood pressure, lipid profiles, glucose metabolism, inflammation, and atherothrombotic disease progression. Given the current obstacles, success of primary prevention remains uncertain. At the same time, the consequences of delay and inaction will inevitably be disastrous, and the sense of urgency mounts. Pathological and epidemiological data confirm that atherosclerosis begins in early childhood, and advances seamlessly and inexorably throughout life. Risk factors in childhood are similar to those in adults, and track between stages of life. When indicated, aggressive treatment should begin at the earliest indication, and be continued for many years. For those patients at intermediate risk according to global risk scores, C-reactive protein, coronary artery calcium, and carotid intima-media thickness are available for further stratification. Using statins for primary prevention is recommended by guidelines, is prevalent, but remains under prescribed. Statin drugs are unrivaled, evidence-based, major weapons to lower cardiovascular risk. Even when low density lipoprotein cholesterol targets are attained, over half of patients continue to have disease progression and clinical events. Though clinical evidence is incomplete, altering or raising the blood high density lipoprotein cholesterol level continues to be pursued. The aim of this review is to point out the attention of key aspects of vulnerable plaques regarding their pathogenesis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.